



US009278016B2

(12) **United States Patent**  
**Busold et al.**

(10) **Patent No.:** **US 9,278,016 B2**  
(45) **Date of Patent:** **Mar. 8, 2016**

(54) **MEDICAL IMPLANT**

(75) Inventors: **Rany Busold**, Charlestown, MA (US);  
**Changcheng You**, Waltham, MA (US);  
**Daniel Concagh**, West Roxbury, MA  
(US); **Lee Core**, Cambridge, MA (US);  
**Kicherl Ho**, Acton, MA (US); **Maria**  
**Palasis**, Wellesley, MA (US); **Upma**  
**Sharma**, Somerville, MA (US); **Greg**  
**Zugates**, Burlington, MA (US)

(73) Assignee: **480 BIOMEDICAL, INC.**, Watertown,  
MA (US)

(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 1133 days.

(21) Appl. No.: **13/032,281**

(22) Filed: **Feb. 22, 2011**

(65) **Prior Publication Data**

US 2011/0238162 A1 Sep. 29, 2011

**Related U.S. Application Data**

(63) Continuation of application No. 12/783,261, filed on  
May 19, 2010.

(60) Provisional application No. 61/179,834, filed on May  
20, 2009, provisional application No. 61/227,308,  
filed on Jul. 21, 2009, provisional application No.  
61/251,984, filed on Oct. 15, 2009.

(51) **Int. Cl.**  
**A61F 2/06** (2013.01)  
**A61F 2/86** (2013.01)  
**A61F 2/90** (2013.01)  
(Continued)

(52) **U.S. Cl.**  
CPC ... **A61F 2/86** (2013.01); **A61F 2/90** (2013.01);  
**A61L 31/06** (2013.01); **A61L 31/10** (2013.01);  
**A61L 31/14** (2013.01); **A61L 31/16** (2013.01);  
**D04C 1/06** (2013.01);  
(Continued)

(58) **Field of Classification Search**

CPC ..... **A61F 2/90**; **A61F 2/86**; **A61F 2/00**;  
**A61F 2/82**; **A61F 2002/82**; **A61F 2002/86**;  
**A61L 31/10**; **A61L 31/14**; **A61L 31/16**;  
**A61L 31/06**  
USPC ..... **623/1.15**, **1.19**, **1.2**, **1.38–1.46**  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

4,243,775 A 1/1981 Rosensaft et al.  
4,300,565 A 11/1981 Rosensaft et al.

(Continued)

**FOREIGN PATENT DOCUMENTS**

EP 1308473 A1 5/2003  
EP 0724436 B1 1/2004

(Continued)

**OTHER PUBLICATIONS**

Examination Report in European Patent Application No.  
GB1019777.0, mailed Jul. 27, 2012 (3 pages).

(Continued)



*Primary Examiner* — Alvin Stewart

(74) *Attorney, Agent, or Firm* — Kacvinsky Daisak Bluni  
PLLC

(57) **ABSTRACT**

Disclosed is a self-expanding medical implant for placement  
within a lumen of a patient. The implant comprises a woven or  
non-woven structure having a substantially tubular configu-  
ration, and is designed to be low-profile such that it is deliv-  
erable with a small diameter catheter. The implant has a high  
recoverability and desired mechanical properties.

**16 Claims, 7 Drawing Sheets**



- (51) **Int. Cl.**  
*A61L 31/06* (2006.01)  
*A61L 31/10* (2006.01)  
*A61L 31/14* (2006.01)  
*A61L 31/16* (2006.01)  
*D04C 1/06* (2006.01)
- (52) **U.S. Cl.**  
 CPC ..... *A61F 2230/0054* (2013.01); *D10B 2403/0112* (2013.01); *D10B 2509/06* (2013.01)
- (56) **References Cited**  
 U.S. PATENT DOCUMENTS
- |               |         |                                 |                |         |                                 |
|---------------|---------|---------------------------------|----------------|---------|---------------------------------|
| 4,461,298 A   | 7/1984  | Shalaby et al.                  | 6,171,232 B1   | 1/2001  | Papandreou                      |
| 4,643,734 A   | 2/1987  | Lin                             | 6,171,609 B1   | 1/2001  | Kunz                            |
| 4,916,193 A   | 4/1990  | Tang et al.                     | 6,179,051 B1   | 1/2001  | Ayub                            |
| 4,920,203 A   | 4/1990  | Tang et al.                     | 6,193,746 B1   | 2/2001  | Strecker                        |
| 4,990,158 A   | 2/1991  | Kaplan et al.                   | 6,207,767 B1   | 3/2001  | Bennett et al.                  |
| 5,066,772 A   | 11/1991 | Tang et al.                     | 6,221,100 B1   | 4/2001  | Strecker                        |
| 5,145,945 A   | 9/1992  | Tang et al.                     | 6,221,997 B1   | 4/2001  | Woodhouse et al.                |
| 5,185,408 A   | 2/1993  | Tang et al.                     | 6,232,434 B1   | 5/2001  | Stamler                         |
| 5,213,580 A   | 5/1993  | Slepian et al.                  | 6,238,687 B1   | 5/2001  | Mao et al.                      |
| 5,256,764 A   | 10/1993 | Tang et al.                     | 6,240,978 B1   | 6/2001  | Gianotti                        |
| 5,274,074 A   | 12/1993 | Tang et al.                     | 6,245,103 B1 * | 6/2001  | Stinson ..... 623/1.22          |
| 5,356,423 A   | 10/1994 | Tihon                           | 6,249,952 B1   | 6/2001  | Ding                            |
| 5,366,504 A * | 11/1994 | Andersen et al. .... 623/1.5    | 6,251,135 B1 * | 6/2001  | Stinson et al. .... 623/1.34    |
| 5,412,068 A   | 5/1995  | Tang et al.                     | 6,261,594 B1   | 7/2001  | Smith                           |
| 5,449,372 A   | 9/1995  | Schmaltz et al.                 | 6,268,390 B1   | 7/2001  | Kunz                            |
| 5,486,593 A   | 1/1996  | Tang et al.                     | 6,270,779 B1   | 8/2001  | Fitzhugh                        |
| 5,516,781 A   | 5/1996  | Morris                          | 6,284,305 B1   | 9/2001  | Ding                            |
| 5,531,735 A   | 7/1996  | Thompson                        | 6,290,722 B1   | 9/2001  | Wang                            |
| 5,545,208 A * | 8/1996  | Wolff et al. .... 623/1.22      | 6,295,714 B1   | 10/2001 | Roychowdhury                    |
| 5,562,725 A   | 10/1996 | Schmitt                         | 6,299,604 B1   | 10/2001 | Ragheb                          |
| 5,563,146 A   | 10/1996 | Morris                          | 6,299,636 B1   | 10/2001 | Schmitt                         |
| 5,595,751 A   | 1/1997  | Bezwada et al.                  | 6,306,421 B1   | 10/2001 | Kunz                            |
| 5,616,608 A   | 4/1997  | Kinsella                        | 6,315,791 B1   | 11/2001 | Gingras et al.                  |
| 5,634,946 A   | 6/1997  | Slepian                         | 6,338,739 B1 * | 1/2002  | Datta et al. .... 623/1.15      |
| 5,650,447 A   | 7/1997  | Keefer                          | 6,342,068 B1   | 1/2002  | Thompson                        |
| 5,665,077 A   | 9/1997  | Rosen                           | 6,368,346 B1   | 4/2002  | Jadhav                          |
| 5,665,728 A   | 9/1997  | Morris                          | 6,379,691 B1   | 4/2002  | Tedeschi                        |
| 5,676,963 A   | 10/1997 | Keefer                          | 6,403,635 B1   | 6/2002  | Kinsella                        |
| 5,703,200 A   | 12/1997 | Bezwada                         | 6,403,759 B2   | 6/2002  | Stamler                         |
| 5,716,981 A   | 2/1998  | Hunter                          | 6,419,694 B1   | 7/2002  | Sandock                         |
| 5,733,925 A   | 3/1998  | Kunz                            | 6,423,092 B2   | 7/2002  | Datta                           |
| 5,741,325 A   | 4/1998  | Chaikof                         | 6,429,232 B1   | 8/2002  | Kinsella                        |
| 5,762,625 A   | 6/1998  | Igaki                           | 6,451,337 B1   | 9/2002  | Smith                           |
| 5,766,710 A   | 6/1998  | Turnlund                        | 6,471,978 B1   | 10/2002 | Stamler                         |
| 5,788,979 A   | 8/1998  | Alt et al.                      | 6,488,701 B1   | 12/2002 | Nolting et al.                  |
| 5,797,877 A   | 8/1998  | Hamilton et al.                 | 6,488,705 B2   | 12/2002 | Schmitt                         |
| 5,799,384 A   | 9/1998  | Schwartz et al.                 | 6,488,951 B2   | 12/2002 | Toone                           |
| 5,824,053 A   | 10/1998 | Khosravi                        | 6,500,203 B1   | 12/2002 | Thompson et al.                 |
| 5,834,582 A   | 11/1998 | Sinclair                        | 6,506,411 B2   | 1/2003  | Hunter                          |
| 5,851,217 A   | 12/1998 | Wolff                           | 6,514,515 B1   | 2/2003  | Williams                        |
| 5,871,535 A   | 2/1999  | Wolff                           | 6,515,009 B1   | 2/2003  | Kunz                            |
| 5,899,935 A   | 5/1999  | Ding                            | 6,537,312 B2   | 3/2003  | Datta et al.                    |
| 5,968,091 A   | 10/1999 | Pinchuk et al.                  | 6,544,544 B2   | 4/2003  | Hunter                          |
| 5,980,564 A * | 11/1999 | Stinson ..... A61F 2/90 606/191 | 6,551,352 B2 * | 4/2003  | Clerc et al. .... 623/1.2       |
| 5,984,957 A   | 11/1999 | Laptewicz                       | 6,569,191 B1   | 5/2003  | Hogan                           |
| 5,993,972 A   | 11/1999 | Reich et al.                    | 6,569,195 B2   | 5/2003  | Yang                            |
| 5,994,444 A   | 11/1999 | Trescony                        | 6,585,764 B2   | 7/2003  | Wright                          |
| 5,997,468 A   | 12/1999 | Wolff et al.                    | 6,589,546 B2   | 7/2003  | Kamath                          |
| 6,004,346 A   | 12/1999 | Wolff et al.                    | 6,592,617 B2   | 7/2003  | Thompson                        |
| 6,004,573 A   | 12/1999 | Rathi et al.                    | 6,599,928 B2   | 7/2003  | Kunz                            |
| 6,005,020 A   | 12/1999 | Loomis                          | 6,605,115 B1   | 8/2003  | Cooke                           |
| 6,013,854 A * | 1/2000  | Moriuchi ..... 623/1.11         | 6,626,936 B2 * | 9/2003  | Stinson ..... 623/1.15          |
| 6,051,021 A   | 4/2000  | Frid                            | 6,626,939 B1 * | 9/2003  | Burnside et al. .... 623/1.11   |
| 6,074,659 A   | 6/2000  | Kunz                            | 6,632,242 B2   | 10/2003 | Igaki                           |
| 6,074,660 A   | 6/2000  | Jamiolkowski et al.             | 6,632,446 B1   | 10/2003 | Hubbell et al.                  |
| 6,083,257 A   | 7/2000  | Taylor                          | 6,645,518 B2   | 11/2003 | Tedeschi                        |
| 6,083,524 A   | 7/2000  | Sawhney et al.                  | 6,656,506 B1   | 12/2003 | Wu et al.                       |
| 6,087,479 A   | 7/2000  | Stamler                         | 6,656,966 B2   | 12/2003 | Garvey                          |
| 6,117,949 A   | 9/2000  | Rathi et al.                    | 6,663,664 B1 * | 12/2003 | Pacetti ..... 623/1.2           |
| 6,120,536 A   | 9/2000  | Ding                            | 6,663,881 B2   | 12/2003 | Kunz                            |
| 6,153,252 A   | 11/2000 | Hossainy et al.                 | 6,706,274 B2   | 3/2004  | Herrmann                        |
| 6,161,399 A   | 12/2000 | Jayaraman                       | 6,719,934 B2 * | 4/2004  | Stinson ..... A61F 2/90 264/103 |
|               |         |                                 | 6,730,064 B2   | 5/2004  | Ragheb                          |
|               |         |                                 | 6,737,447 B1   | 5/2004  | Smith                           |
|               |         |                                 | 6,743,462 B1   | 6/2004  | Pacetti                         |
|               |         |                                 | 6,753,454 B1   | 6/2004  | Smith                           |
|               |         |                                 | 6,776,796 B2 * | 8/2004  | Falotico et al. .... 623/1.46   |
|               |         |                                 | 6,790,228 B2   | 9/2004  | Hossainy                        |
|               |         |                                 | 6,805,898 B1   | 10/2004 | Wu et al.                       |
|               |         |                                 | 6,808,536 B2   | 10/2004 | Wright                          |
|               |         |                                 | 6,855,366 B2   | 2/2005  | Smith                           |
|               |         |                                 | 6,869,973 B2   | 3/2005  | Garvey                          |
|               |         |                                 | 6,875,840 B2   | 4/2005  | Stamler                         |
|               |         |                                 | 6,884,429 B2   | 4/2005  | Koziak                          |
|               |         |                                 | 6,887,266 B2   | 5/2005  | Williams et al.                 |
|               |         |                                 | 6,887,485 B2   | 5/2005  | Fitzhugh                        |
|               |         |                                 | 6,908,622 B2   | 6/2005  | Barry                           |
|               |         |                                 | 6,932,930 B2   | 8/2005  | DeSimone et al.                 |

(56)

## References Cited

## U.S. PATENT DOCUMENTS

6,939,376 B2 *	9/2005	Shulze et al. ....	623/1.42	7,776,381 B1	8/2010	Tang et al.	
6,949,112 B1	9/2005	Sridharan et al.		7,776,382 B2	8/2010	Chappa et al.	
6,974,475 B1	12/2005	Wall		7,794,495 B2	9/2010	Gale et al.	
6,991,647 B2	1/2006	Jadhav		7,794,776 B1	9/2010	Limon et al.	
6,997,948 B2	2/2006	Stinson		7,794,777 B2	9/2010	Kokish et al.	
7,005,137 B1	2/2006	Hossainy et al.		7,833,261 B2	11/2010	Chen et al.	
7,008,397 B2	3/2006	Tweden		7,857,844 B2	12/2010	Norton et al.	
7,011,678 B2	3/2006	Tenerz		7,875,233 B2	1/2011	Huang et al.	
7,018,401 B1 *	3/2006	Hyodoh et al. ....	623/1.12	7,875,283 B2	1/2011	Hossainy et al.	
7,029,495 B2	4/2006	Stinson		7,879,953 B2	2/2011	Pacetti	
7,063,884 B2	6/2006	Hossainy et al.		7,901,452 B2	3/2011	Gale et al.	
7,070,615 B1	7/2006	Igaki		7,919,162 B2	4/2011	DeSimone et al.	
7,087,709 B2	8/2006	Stamler		7,923,022 B2	4/2011	Wang et al.	
7,101,566 B2	9/2006	Rosenblatt et al.		7,951,185 B1	5/2011	Abbate et al.	
7,141,061 B2	11/2006	Williams et al.		7,971,333 B2	7/2011	Gale et al.	
7,160,323 B2	1/2007	Pulnev et al.		7,972,616 B2	7/2011	Debrow et al.	
7,160,592 B2	1/2007	Rypacek et al.		7,985,441 B1	7/2011	Tang et al.	
7,163,554 B2	1/2007	Williams et al.		8,003,156 B2	8/2011	Van Sciver	
7,163,562 B2	1/2007	Datta et al.		8,016,879 B2	9/2011	Gale et al.	
7,166,133 B2	1/2007	Evans et al.		8,043,553 B1	10/2011	Durcan	
7,217,286 B2	5/2007	Falotico		8,137,396 B2 *	3/2012	Busold et al. ....	623/1.38
7,220,816 B2	5/2007	Pacetti et al.		8,545,550 B2 *	10/2013	Shulze et al. ....	623/1.42
7,223,286 B2	5/2007	Wright		8,585,730 B2 *	11/2013	Eaton et al. ....	606/199
7,229,473 B2	6/2007	Falotico		8,585,731 B2 *	11/2013	Abbate et al. ....	606/199
7,252,679 B2	8/2007	Fischell et al.		8,814,930 B2 *	8/2014	Zheng	A61F 2/82
7,279,005 B2	10/2007	Stinson		9,119,905 B2 *	9/2015	Zheng	623/1.2
7,279,175 B2	10/2007	Chen		2003/0040771 A1 *	2/2003	Hyodoh	A61F 2/82
7,285,287 B2	10/2007	Williams et al.					A61F 2/90
7,291,165 B2	11/2007	Rosenthal		2004/0044405 A1	3/2004	Wolff	606/200
7,292,885 B2	11/2007	Scott		2004/0068078 A1	4/2004	Milbocker et al.	
7,300,662 B2	11/2007	Falotico		2004/0106987 A1	6/2004	Palasis	
7,318,944 B2 *	1/2008	Neary	427/2.24	2004/0181277 A1	9/2004	Furst	
7,318,945 B2	1/2008	Thornton		2004/0220665 A1 *	11/2004	Hossainy	A61L 27/34
7,348,319 B2	3/2008	Hrabie					623/1.42
7,348,364 B2	3/2008	Shalaby		2004/0260272 A1	12/2004	Friedman et al.	
7,361,726 B2	4/2008	Pacetti et al.		2005/0142315 A1	6/2005	DeSimone et al.	
7,378,106 B2	5/2008	Hossainy		2005/0214343 A1	9/2005	Tremble	
7,387,641 B2	6/2008	Schmitt		2005/0214344 A1	9/2005	Barrows et al.	
7,390,333 B2	6/2008	Dutta		2006/0002977 A1	1/2006	Dugan	
7,416,559 B2	8/2008	Shalaby		2006/0100568 A1	5/2006	Tan	
7,419,502 B2	9/2008	Pulnev et al.		2006/0121087 A1	6/2006	Williams et al.	
7,419,503 B2	9/2008	Pulnev et al.		2006/0129222 A1 *	6/2006	Stinson	A61F 2/90
7,419,504 B2	9/2008	Hossainy					623/1.2
7,425,218 B2	9/2008	Keefer		2006/0147492 A1	7/2006	Hunter et al.	
7,438,712 B2	10/2008	Chouinard		2006/0195059 A1	8/2006	Freyman et al.	
7,445,628 B2	11/2008	Ragheb		2006/0204738 A1	9/2006	Dubrow et al.	
7,470,283 B2	12/2008	Dutta et al.		2006/0246108 A1	11/2006	Pacetti et al.	
7,488,444 B2	2/2009	Furst et al.		2007/0026132 A1	2/2007	Williams et al.	
7,491,233 B1	2/2009	Ding		2007/0038284 A1	2/2007	Williams et al.	
7,491,234 B2	2/2009	Palasis et al.		2007/0093889 A1	4/2007	Wu et al.	
7,498,385 B2	3/2009	Swetlin et al.		2007/0110787 A1	5/2007	Hossainy et al.	
7,504,125 B1	3/2009	Pacetti et al.		2007/0123539 A1	5/2007	Wu	
7,517,338 B2	4/2009	Freyman et al.		2007/0185561 A1 *	8/2007	Schmitz	A61L 17/12
RE40,816 E	6/2009	Taylor et al.					623/1.2
7,556,842 B2	7/2009	Worsham et al.		2007/0255422 A1	11/2007	Wei et al.	
7,563,483 B2	7/2009	Hossainy et al.		2007/0271763 A1	11/2007	Huang et al.	
7,585,516 B2	9/2009	Pacetti		2007/0280851 A1	12/2007	Freeman et al.	
7,594,928 B2	9/2009	Headley, Jr. et al.		2007/0281250 A1	12/2007	Aono	
7,604,699 B2	10/2009	Chen et al.		2007/0282247 A1	12/2007	Desai et al.	
7,611,533 B2	11/2009	Bates et al.		2007/0283552 A1	12/2007	Gale et al.	
7,618,448 B2	11/2009	Schmitz et al.		2007/0289117 A1 *	12/2007	Huang	A61F 2/958
7,648,725 B2	1/2010	Van Sciver et al.					29/508
7,658,880 B2	2/2010	Wu		2007/0299504 A1	12/2007	Gale et al.	
7,673,379 B1 *	3/2010	Pacetti	A61F 2/958 29/447	2008/0008739 A1	1/2008	Hossainy et al.	
7,682,647 B2	3/2010	Hossainy et al.		2008/0091262 A1	4/2008	Gale et al.	
7,682,648 B1	3/2010	Ding et al.		2008/0145393 A1	6/2008	Trollas et al.	
7,718,213 B1	5/2010	Scheer		2008/0147161 A1	6/2008	Chen et al.	
7,731,740 B2 *	6/2010	LaFont et al. ....	623/1.11	2008/0147164 A1	6/2008	Gale et al.	
7,736,386 B2	6/2010	Pulnev et al.		2008/0167724 A1 *	7/2008	Ruane et al. ....	623/1.5
7,758,908 B2	7/2010	Pham et al.		2008/0177375 A1 *	7/2008	Chen et al. ....	623/1.15
7,761,968 B2 *	7/2010	Huang et al. ....	29/447	2008/0275539 A1	11/2008	Williams et al.	
7,763,068 B2	7/2010	Pulnev et al.		2008/0300669 A1 *	12/2008	Hossainy	623/1.15
7,763,308 B2	7/2010	Chen et al.		2008/0306592 A1 *	12/2008	Wang	A61L 31/10
7,767,726 B2	8/2010	Sutermeister et al.					623/11.11
				2009/0005860 A1	1/2009	Gale et al.	
				2009/0018643 A1	1/2009	Hashi et al.	
				2009/0062904 A1	3/2009	Furst	
				2009/0099600 A1	4/2009	Moore et al.	

(56)

## References Cited

## U.S. PATENT DOCUMENTS

2009/0138076	A1	5/2009	Palasis et al.	
2009/0216104	A1	8/2009	Desimone et al.	
2009/0285974	A1	11/2009	Kerrigan et al.	
2009/0286761	A1	11/2009	Cheng et al.	
2009/0304769	A1	12/2009	Kunkel et al.	
2010/0198344	A1	8/2010	Omura et al.	
2010/0298952	A1	11/2010	Busold et al.	
2011/0009949	A1*	1/2011	Stankus et al.	623/1.22
2011/0238162	A1	9/2011	Busold et al.	
2011/0301259	A1*	12/2011	Su et al.	523/113
2011/0319987	A1	12/2011	Palasis et al.	
2012/0123521	A1*	5/2012	Headley et al.	623/1.15
2013/0006350	A1*	1/2013	Shulze et al.	623/1.16
2013/0138206	A1*	5/2013	Sudhir	A61F 2/82 623/1.38
2013/0196128	A1*	8/2013	Friedrich et al.	428/209
2013/0211490	A1*	8/2013	Sudhir	A61K 31/436 623/1.11
2013/0236498	A1*	9/2013	Mangiardi	A61K 31/436 424/400
2015/0081000	A1*	3/2015	Hossainy	A61F 2/88 623/1.2
2015/0282969	A1*	10/2015	Pacetti	A61F 2/958 29/515

## FOREIGN PATENT DOCUMENTS

EP	1382628	A1	1/2004
EP	1400218	A1	3/2004
EP	1700872	A2	9/2006
GB	2475778		6/2011
WO	WO 99/34750		7/1999
WO	WO 2008/076383	A2	6/2008
WO	WO 2009/158290	A2	12/2009

## OTHER PUBLICATIONS

Hietala et al., Thrombosis and haemostatis, vol. 92, No. 6 2004, "Platelet deposition on stainless steel, spiral, and braided polyactide stents", pp. 1394-1401.

International Search Report dated Jul. 21, 2010 for International Patent Application No. PCT/US2010/035417, (2pgs).

International Search Report dated Mar. 22, 2011 (2 pages).

G.A. Abraham, A. Marcos-Fernandez, J.S. Roman, Bioresorbable poly(ester-ether urethanes) from L-lysine diisocyanate and triblock copolymers with different hydrophilic character, J. Biomed. Mater. Res. A 2006 76, 729-736.

P. Bruin, J. Smedinga, A. J. Pennings, M.F. Jonkman, Biodegradable lysine diisocyanate-based poly(glycolide-co-ε-caprolactone)-urethane network in artificial skin, Biomaterials 1990, 11, 291-295.

A. O. Helminen, H. Korhonen, J. V. Seppala, Cross-linked poly(ε-caprolactone/D,L-lactide) copolymers with elastic properties, Macromol. Chem. Phys. 2002, 203, 2630-2639.

L. Pinchuck, et al. (2008) Medical applications of poly(styrene-block-isobutylene-block-styrene) ("SIBS"), Biomaterials, 29, 448-460.

J.E. Puskas, et al. (2004) Biomedical application of commercial polymers and novel polyisobutylene-based thermoplastic elastomers for soft tissue replacement, Biomacromolecules, 5, 1141-1154.

J.E. Puskas, et al. (2009) Drug-eluting stent coatings, Wiley Interdiscip. Rev. Nanomed, Nanobiotechnol., 1, 451-462.


Examination Report dated Jan. 21, 2011, issued in GB Application No. GB1008366.5.


Search and Examination Report dated Sep. 1, 2010 issued in GB Application No. GB1008366.5.

Examination Report dated May 5, 2011, issued in GB Application No. GB1008366.5.

Examination Report dated Feb. 6, 2013 in United Kingdom Patent Application No. GB1222543.9.

\* cited by examiner








FIG. 3




FIG. 4




FIG. 5




FIG. 6






FIG. 7




FIG. 8




FIG. 9

1

**MEDICAL IMPLANT**

This application is a continuation of U.S. patent application Ser. No. 12/783,261, filed May 19, 2010, which claims the benefit of priority to U.S. Provisional Application 61/179,834, filed May 20, 2009, by inventors Lee Core et al., entitled “Medical Implant”, and claims the benefit of priority to U.S. Provisional Application 61/227,308, filed Jul. 21, 2009, by inventors Lee Core et al., entitled “Medical Implant”, and claims the benefit of priority to U.S. Provisional Application 61/251,984, filed Oct. 15, 2009, by inventors Lee Core et al.

**FIELD OF THE INVENTION**

The present invention relates to medical implants, and more specifically, to self-expanding medical implants that are intended for placement within a lumen or cavity of a patient.

**BACKGROUND**

A variety of medical conditions are treatable by the implantation of tubular devices into natural body lumens. For example, it is commonplace to implant metallic stents into the coronary arteries of patients with heart disease following balloon angioplasty to minimize the risk that the arteries will undergo restenosis. Recently, commercial stents have included drug-eluting polymer coatings that are designed to further decrease the risk of restenosis. Other examples of conventional tubular medical implants include woven grafts and stent-grafts that are used to span vascular aneurysms, polymeric tubes and catheters that are used to bypass strictures in the ureter and urethra, and stents that are used in the peripheral vasculature, prostate, and esophagus.

Despite the evolution of metallic stents, they continue to have limitations such as the possibility of causing thrombosis and vascular remodeling. While the use of biodegradable and biostable polymeric materials for stents and other implantable devices has been proposed to eliminate the possible long-term effects of permanent implants, the use of such materials has been hindered by relatively poor expandability and mechanical properties. For example, the expansion characteristics and radial strength of prototype stents made from biodegradable and biostable polymeric materials has been significantly lower than that of metallic stents. This is particularly the case where such stents are low profile and make use of small diameter fibers or thin walled struts that comprise the stent body. Furthermore, the degradation rate and the manner in which such devices degrade in the body has been difficult to control. Finally, where such devices are used as a drug delivery vehicle, the drug elution rate has been difficult to reproducibly characterize.

There is therefore a need for low-profile, self-expanding implantable tubular devices that have sufficient expansion characteristics, strength and other mechanical and drug release properties that are necessary to effectively treat the medical conditions for which they are used.

**SUMMARY**

In one aspect, the present invention includes an implantable medical device for placement within a lumen or cavity of a patient. In another aspect, the present invention includes a method of loading the medical device into a delivery catheter just prior to being implanted into a patient. In another aspect, the present invention includes a method of treating a patient by delivering the medical device to a target location within the

2

patient. In yet another aspect, the present invention includes a kit that comprises the implantable medical device.

The implantable medical devices of the present invention are generally tubular, self-expanding devices. The devices have a combination of structure, composition, and/or strengthening means that provide them with exceptional expandability and mechanical properties when compared with conventional self-expanding devices.

In one embodiment, the implantable medical device comprises a self-expanding tubular structure that comprises at least one strand. The at least one strand comprises a first polymer characterized by a modulus of elasticity greater than about 1 GPa. The implantable medical device further includes a strengthening means comprising a second polymer at least partially coating the strand. The second polymer is characterized by a percent elongation to break that is greater than about 150 percent at body temperature (37° C.). The second polymer increases the mass of the self-expanding tubular structure by at least about 20 percent.

In another embodiment, the implantable medical device comprises a self-expanding tubular structure that comprises at least one strand comprising a first polymer. The implantable medical device further includes a strengthening means comprising a second polymer at least partially coating the strand. The second polymer comprises a first elastic component having a Tg less than about 37° C. and a second component that is harder than the first component. The second polymer increases the mass of the self-expanding tubular structure by at least about 20 percent.

In other embodiments, the implantable medical device comprises a self-expanding tubular structure comprising a unitary framework rather than at least one strand. In certain embodiments, the implantable medical device comprises a therapeutic agent for delivery into a patient's body.

**BRIEF DESCRIPTION OF THE DRAWINGS**

FIG. 1 is a side view of an implantable braided medical device, in accordance with an embodiment of the present invention.

FIG. 2 is a side view of an implantable unitary framework medical device, in accordance with an embodiment of the present invention.

FIG. 3 is a cross-sectional view of a strand of an implantable medical device in accordance with an embodiment of the present invention that includes a support coating.

FIG. 4 is a side view of a strand of an implantable medical device in accordance with an embodiment of the present invention that includes discrete areas of therapeutic agent thereon.

FIG. 5 is a cross-sectional view of a strand of an implantable medical device in accordance with an embodiment of the present invention that includes a therapeutic agent coating and a topcoat.

FIG. 6 is an end view of an implantable medical device in accordance with an embodiment of the present invention.

FIG. 7 is a graph of diameter recovery as a function of support coating weight, for certain embodiments of the present invention.

FIG. 8 is a graph of diameter recovery as a function of gel content within a support coating, for certain embodiments of the present invention.

FIG. 9 is a graph of COF values of certain embodiments of the present invention, as well as for known commercial self-expanding stents.

## DESCRIPTION OF PREFERRED EMBODIMENTS

The present invention provides for self-expanding medical implants that have expansion characteristics and mechanical properties that render them suitable for a broad range of applications involving placement within bodily lumens or cavities. As used herein, “device” and “implant” are used synonymously. Also as used herein, “self-expanding” is intended to include devices that are crimped to a reduced configuration for delivery into a bodily lumen or cavity, and thereafter tend to expand to a larger suitable configuration once released from the delivery configuration, either without the aid of any additional expansion devices or with the partial aid of balloon-assisted or similarly-assisted expansion. When compared with conventional self-expanding medical implants, the implants of the present invention recover to an exceptionally high percentage of their manufactured diameter after being crimped and held in a small diameter for delivery into a bodily lumen. Moreover, when compared with conventional self-expanding implants and particularly polymeric implants, the implants of the present invention are characterized by much improved strength and other desired mechanical properties. As used herein, “strength” and “stiffness” are used synonymously to mean the resistance of the medical implants of the present invention to deformation by radial forces. Examples of strength and stiffness measurements, as used to characterize the medical implants of the present invention, include radial resistive force and chronic outward force, as further defined herein.

In one embodiment shown in FIG. 1, the implant **100** preferably comprises at least one strand woven together to form a substantially tubular configuration having a longitudinal dimension **130**, a radial dimension **131**, and first and second ends **132**, **133** along the longitudinal dimension. As used herein, “woven” is used synonymously with “braided.” For example, the tubular configuration may be woven to form a tubular structure comprising two sets of strands **110** and **120**, with each set extending in an opposed helix configuration along the longitudinal dimension of the implant. The sets of strands **110** and **120** cross each other at a braid angle **140**, that may be constant or may change along the longitudinal dimension of the implant. Preferably, there are between about 16 and about 96 strands used in the implants of the present invention, and the braid angle **140** is within the range of about 90 degrees to about 135 degrees throughout the implant. The strands are woven together using methods known in the art, using known weave patterns such as Regular pattern “1 wire, 2-over/2-under”, Diamond half load pattern “1 wire, 1-over/1-under”, or Diamond pattern “2 wire, 1-over/1-under”.

Although the strands may be made from biostable polymeric or metallic materials, they are preferably made from at least one biodegradable polymer that is preferably fully absorbed within about two years of placement within a patient, and more preferably within about one year of placement within a patient. In some embodiments, the strands are fully absorbed within about six or fewer months of placement within a patient. The first and second strand sets **110**, **120** may be made from the same or different biodegradable polymer. Non-limiting examples of biodegradable polymers that are useful in the at least one strand of the present invention include poly lactic acid (PLA), poly glycolic acid (PGA), poly trimethylene carbonate (PTMC), poly caprolactone (PCL), poly dioxanone (PDO), and copolymers thereof. Preferred polymers are poly(lactic acid co-glycolic acid) (PLGA) having a weight percentage of up to about 20% lactic acid, or greater than about 75% lactic acid (preferably PLGA

85:15), with the former being stronger but degrading in the body faster. The composition of PLGA polymers within these ranges may be optimized to meet the mechanical property and degradation requirements of the specific application for which the implant is used. For desired expansion and mechanical property characteristics, the materials used for the strands preferably have an elastic modulus within the range of about 1 to about 10 GPa, and more preferably within the range of about 6-10 GPa.

To facilitate the low-profile aspects of the present invention (e.g., the delivery of the implants into small diameter bodily lumens or cavities), the strands used in the implant **100** preferably have a diameter in the range of from about 125 microns to about 225 microns, and are more preferably less than about 150 microns in diameter. The use of small diameter strands results in an implant with minimal wall thickness and the preferred ability to collapse (i.e., to be crimped) within low diameter catheter delivery systems. Where multiple strands are used, they may be of substantially equal diameters within this range, or first strand set **110** may be of a different general diameter than second strand set **120**. In either event, the diameters of strands are chosen so as to render the implant **100** preferably deliverable from a 10 French delivery catheter (i.e., 3.3 mm diameter) or smaller, and more preferably from a 7 French delivery catheter (i.e., 2.3 mm diameter) or smaller. The ability to place the implant of the present invention into small diameter delivery catheters allows for its implantation into small diameter bodily lumens and cavities, such as those found in the vascular, biliary, uro-genital, iliac, and tracheal-bronchial anatomy. Exemplary vascular applications include coronary as well as peripheral vascular placement, such as in the superficial femoral artery (SFA). It should be appreciated, however, that the implants of the present invention are equally applicable to implantation into larger bodily lumens, such as those found in the gastrointestinal tract.

In another embodiment of the present invention, the implant is a non-woven, self-expanding structure, such as a unitary polymeric framework. As shown in FIG. 2, the non-woven implant **100** is preferably characterized by a regular, repeating pattern such as a lattice structure. The use of a unitary framework may provide a reduced profile when compared to the use of woven strands, which yield a minimum profile that is the sum of the widths of overlapping strands. In addition, a unitary framework eliminates the possible change in length of the implant associated with crimping and subsequent expansion, known as foreshortening, which is common in braided stents. When the implant **100** is a unitary framework, it is fabricated using any suitable technique, such as by laser cutting a pattern into a solid polymer tube. In a preferred embodiment, when the implant **100** is a unitary framework, it is formed by laser cutting and includes a wall thickness of between about 75 and about 100 microns. It should be recognized that while the present invention is described primarily with reference to woven strand configurations, aspects of the present invention are equally applicable to non-woven, self-expanding structures unless necessarily or expressly limited to woven configurations.

There are a variety of strengthening means that are useful in the present invention to help provide the expansion and mechanical properties that are needed to render the implant **100** effective for its intended purpose. Two measures of such mechanical properties that are used herein are “radial resistive force” (“RRF”) and “chronic outward force” (“COF”). RRF is the force that the implant applies in reaction to a crimping force, and COF is the force that the implant applies against a static abutting surface. Without wishing to be bound

by theory, the inventors believe that the self-expanding implants of the present invention should preferably recover to a high percentage of their as-manufactured configuration after being crimped for insertion into the body, and the thus expanded implant should have a relatively high RRF to be able to hold open bodily lumens and the like, yet have a relatively low COF so as to avoid applying possibly injurious forces against the walls of bodily lumens or the like. For example, the implants of the present invention preferably expand to at least 90% of their as manufactured configuration after being crimped, have an RRF of at least about 200 mm Hg, have an acute COF (at the time of delivery into a bodily lumen or cavity) of about 40-200 mm Hg, and a COF of less than about 10 mm Hg after about 28 days in vivo.

In one embodiment, the strengthening means is a support coating **410** on at least one of the strands of the implant **100**. Although referred to herein as a "coating," the support coating **410** does not necessarily coat the entire implant **100**, and may not form a discrete layer over the strands or unitary framework of the implant **100**; rather, the support coating **410** and underlying strands or unitary framework may be considered as a composite structure. The support coating **410** is made from an elastomeric polymer that, due to its elastic nature when compressed or elongated, applies a force to implant **100** that acts in favor of radial expansion and axial contraction, thus enhancing radial strength. The polymer of the support coating **410** is preferably biodegradable. Alternatively, the support coating **410** is made from a shape memory polymer or a polymer that otherwise contracts upon heating to body temperature. The inventors have surprisingly found that the use of support coatings on the polymeric implants of the present invention can result in the recovery of more than 90% of implant diameter post-crimping, and yield significantly higher radial forces when compared with uncoated implants or even with self-expanding metallic stents. The support coating **410** may be applied as a conformal coating (as shown in cross-section of an individual strand in FIG. 3), may be partially applied to one or more individual strands such that the support coating **410** is applied to only a portion of the implant along its longitudinal dimension, or may be applied to only the inner or outer diameter of one or more individual strands. Also, the support coating **410** may optionally vary in weight along the length of the implant; for example, the ends of the implant may be coated with a thicker layer than the mid-section to provide added support to the ends of the implant. In addition, the support coating may accumulate at the crossover points or "nodes" of the woven device, which has the effect of aiding in diameter recovery and the achievement of preferred COF and RRF values.

Examples of polymer materials used for the support coating **410** include suitable thermoplastic or thermoset elastomeric materials that yield the elongation, mechanical strength and low permanent deformation properties when combined with the implant strand(s). The inventors have found examples of suitable polymers to include certain random copolymers such as poly(lactic acid-co-caprolactone) (PLCL), poly(glycolide-co-caprolactone) (PGCL), and poly(lactic acid-co-dioxanone) (PLDO), certain homopolymers such as poly(trimethylene carbonate) (PTMC), and copolymers and terpolymers thereof. Such polymers are optionally crosslinked with a crosslinker that is bi- or multi-functional, polymeric, or small molecule to yield a thermoset polymer having a glass transition temperature ( $T_g$ ) that is preferably lower than body temperature (37° C.), more preferably lower than room temperature (25° C.), and most preferably lower

than about 5° C. The thermoset elastomers provide a high elongation to break with low permanent deformation under cyclic mechanical testing.

In one preferred embodiment, the polymer material used for the support coating **410** is a biodegradable thermoset elastomer synthesized from a four arm PGCL polymer having a weight ratio of approximately 50:50 GA:CL that is crosslinked with hexamethylene diisocyanate (HDI) to give a polyester with urethane crosslinks. Without wishing to be bound by theory, the inventors believe that the combination of the elastic segment (polyester portion) and the interactions (such as hydrogen bonding, allophanate or biuret formation) between the urethane segments of such polymers, in addition to a certain crosslinking density, yields preferred properties such as a high degree of elastic recovery under cyclic mechanical strain and high overall elasticity.

In other preferred embodiments, the support coating comprises PLCL having a weight ratio of approximately 50:50 PL:CL. In yet another preferred embodiment, a PLCL 50:50 crosslinked with hexamethylene diisocyanate support coating is applied to a PLGA 75:25 braided implant.

The polymer material used for support coating **410** may be optimized for desired mechanical properties. For example, the inventors have found that the molecular weight of such polymers may be manipulated to enhance coating performance. As an example, when PLCL 50:50 crosslinked with hexamethylene diisocyanate is used as the support coating of the present invention, the inventors have found that a molecular weight ( $M_n$ ) between about 30 kDa and 100 kDa, preferably from 33 k to 65 k, results in a lower modulus of elasticity and a higher strain to fracture, thus making the coating better able to adhere to a PLGA braided implant during crimping and post-crimping expansion and therefore less likely to fracture during deployment. Similarly, the inventors have found that when PGCL 50:50 crosslinked with hexamethylene diisocyanate is used as the support coating of the present invention, a molecular weight ( $M_n$ ) from 8 kDa to 20 kDa does not yield an appreciable change in properties, but that a further increase in molecular weight to 50 kDa results in a four-fold increase in the strain at failure of the coating material. As such, a preferred range of molecular weight ( $M_n$ ) for PGCL used in the implants of the present invention is about 23 kDa to about 50 kDa. Additionally, the inventors have found that the viscosity of the spray coating solution, the weight percent of crosslinker used in the spray coating solution, and the temperature and duration of the support coating crosslinking process can be optimized to provide preferred coating morphologies and radial forces.

The support coating **410** is coated onto the surface of the implant **100** using any suitable method, such as spraying, dipping, electrospraying, rolling, and the like. If implant **100** is a woven structure, the support coating **410** may be applied to individual strands prior to forming the woven structure, or to the woven structure after the formation thereof. In this case, owing to surface tension, the coating preferably collects at intersection points between strands. If implant **100** is a non-woven structure, the support coating **410** may be applied, for example, to a solid polymer tube either before or after the removal of material such as by laser cutting to form a patterned, non-woven structure.

The amount of support coating **410** applied to the implant **100** has been identified as one of the factors that contribute to the expansion characteristics and mechanical strength of the implant. Preferably, the application of the support coating **410** increases the weight of the uncoated implant **100** by about 20% to about 100%, more preferably, by about 24% to about 70%, and most preferably by about 30% to about 60%.

In another embodiment, the strengthening means includes the attachment of strand sets **110**, **120** at one or more intersections of the strands along the longitudinal dimension of the implant **100**. Such attachment may be achieved by use of an adhesive, or by fusing the strands at predetermined intersections such as by heat, laser, or ultrasound. In this embodiment, the strands comprise materials having sufficient elasticity such that the local strains induced by the adhesive/welded joints would not cause plastic deformation thereof.

In yet another embodiment, the strengthening means includes the incorporation of additives into one or more of the strands. In one example, such additives are neutralizing agents such as calcium salts (e.g., calcium carbonate or calcium phosphate) or other salts such as barium salts that increase the mechanical strength of the strands into which they are incorporated, and further act to neutralize any acidic byproducts resulting from the degradation of the strand material(s). In another example, such additives are plasticizers such as polyethylene glycol (PEG) that dissolve from the strand(s) in vivo, thus increasing the flexibility of the strand(s) and the implant over time.

In one embodiment, the implant **100** delivers one or more therapeutic agents at the site of implantation. The therapeutic agent(s) may be applied to one or more strands for delivery therefrom in a number of ways. In one example, the therapeutic agent(s) are embedded within a conformal polymer coating **210** that adheres to one or more individual strands of the implant **100**. Such a coating **210** is preferably made from a biodegradable polymer admixed with the therapeutic agent(s) such that the agent is eluted from the polymer over time, or is released from the coating as it degrades in vivo. In another example as shown in FIG. 4, one or more therapeutic agents are applied in discrete areas **220** on one or more individual strands (shown as length of individual strand). Like coating **210**, discrete areas **220** are preferably made from a biodegradable polymer admixed with the therapeutic agent(s) and eluted from the polymer over time, or are released from the coating as it degrades in vivo. In either of coating **210** or discrete areas **220**, the biodegradable polymer may be the same as or different from the biodegradable polymer(s) used in the strands of the implant. In yet another example, the therapeutic agent(s) are admixed within the strand(s) of the implant **100** such that the agent(s) are eluted from the one or more strands over time, or are released from the one or more strands as the strand(s) degrade in vivo. In yet another example, the therapeutic agent(s) are admixed within a support coating, as described herein. Likewise, in embodiments in which the implant **100** is a non-woven structure, the therapeutic agent(s) may be admixed with the polymer used to fabricate the implant **100**.

The therapeutic agent(s) used in the present invention are any suitable agents having desired biological effects. For example, where the implant of the present invention is used to combat restenosis, the therapeutic agent is selected from anti-thrombogenic agents such as heparin, heparin derivatives, urokinase, and PPACK (dextrophenylalanine proline arginine chloromethylketone), enoxaparin, hirudin; anti-proliferative agents such as angiopoietin, or monoclonal antibodies capable of blocking smooth muscle cell proliferation, acetylsalicylic acid, paclitaxel, sirolimus, tacrolimus, everolimus, zotarolimus, vincristine, sprycel, amlodipine and doxazosin; anti-inflammatory agents such as glucocorticoids, betamethasone, dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, rosiglitazone, mycophenolic acid, and mesalamine; immunosuppressants such as sirolimus, tacrolimus, everolimus, zotarolimus, and dexamethasone; anti-neoplastic/antiproliferative/anti-mitotic agents such as pacli-

taxel, 5-fluorouracil, cisplatin, vinblastine, cladribine, vincristine, epothilones, methotrexate, azathioprine, halofuginone, adriamycin, actinomycin and mutamycin; endostatin, angiostatin and thymidine kinase inhibitors, and its analogs or derivatives; anesthetic agents such as lidocaine, bupivacaine, and ropivacaine; anti-coagulants such as D-Phe-Pro-Arg chloromethyl ketone, an RGD peptide-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin (aspirin is also classified as an analgesic, antipyretic and anti-inflammatory drug), dipyridamole, hirudin, prostaglandin inhibitors, platelet inhibitors and anti-platelet agents such as trapidil or liprostin, tick antiplatelet peptides; DNA demethylating drugs such as 5-azacytidine, which is also categorized as a RNA or DNA metabolite that inhibit cell growth and induce apoptosis in certain cancer cells; vascular cell growth promoters such as growth factors, Vascular Endothelial Growth Factors (VEGF, all types including VEGF-2), growth factor receptors, transcriptional activators, and translational promoters; vascular cell growth inhibitors such as antiproliferative agents, growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; cholesterol-lowering agents; vasodilating agents; and agents which interfere with endogenous vasoactive mechanisms; anti-oxidants, such as probucol; antibiotic agents, such as penicillin, cefoxitin, oxacillin, tobramycin; angiogenic substances, such as acidic and basic fibroblast growth factors, estrogen including estradiol (E2), estriol (E3) and 17-Beta Estradiol; drugs for heart failure, such as digoxin, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors including captopril and enalapril, statins and related compounds; and macrolides such as sirolimus and everolimus. Preferred therapeutic agents used in the present invention to treat restenosis and similar medical conditions include sirolimus, everolimus, zotarolimus, vincristine, sprycel, dexamethasone, and paclitaxel. Also preferred is the use of agents that have a primary mechanism of action of inhibiting extracellular matrix remodeling, and a secondary mechanism of action of inhibiting cell proliferation. Such agents include 5-fluorouracil, valsartan, doxycycline, carvedilol, curcumin, and tranilast.

Coating **210** or areas **220** containing one or more therapeutic agents are applied to implant **100** by any suitable method, such as spraying, electrospraying, rolling, dipping, chemical vapor deposition, and potting. As an alternate embodiment, coating **210** or areas **220** is further coated with a biodegradable topcoat as shown in FIG. 5 (individual strand shown in cross-section), that acts to regulate the delivery of the therapeutic agent from coating **210** or areas **220** into bodily tissue. In one embodiment, the topcoat **211** acts as a diffusion barrier such that the rate of delivery of the therapeutic agent(s) are limited by the rate of its diffusion through the topcoat **211**. In another embodiment, the therapeutic agent(s) cannot diffuse through the topcoat **211** such that delivery thereof is simply delayed until the degradation of the topcoat **211** is complete. The topcoat **211** preferably comprises a biodegradable polymer that is the same as or different from that of the coating **210** or the strands. If implant **100** is a woven structure, coatings **210**, **220**, or **211** may be applied to individual strands prior to forming into the woven structure, or to the woven structure after the formation thereof. If implant **100** is a non-woven structure, coatings **210**, **220**, or **211** may be applied, for example, to a solid polymer tube either before or after the

removal of material such as by laser cutting to form a patterned, non-woven structure. In embodiments that include support coating **410**, the coatings **210**, **220**, and/or **211** are preferably applied over such support coating **410**, or the support coating **410** itself may include the therapeutic agent(s).

The implant **100** of the present invention is self-expanding in that it is manufactured at a first diameter, is subsequently reduced or "crimped" to a second, reduced diameter for placement within a delivery catheter, and self-expands towards the first diameter when extruded from the delivery catheter at an implantation site. The first diameter is preferably at least 20% larger than the diameter of the bodily lumen into which it is implanted. The implant **100** is preferably designed to recover at least about 80% and up to about 100% of its manufactured, first diameter. The inventors have found that implants in accordance with the present invention have a recovery diameter greater than 80%, and preferably greater than 90%, of the manufactured, first diameter after being crimped into exemplary delivery catheters of either 1.8 mm or 2.5 mm inner diameter and held for one hour at either room temperature (25° C.) or body temperature (37° C.). Such implants a braided structure comprising 32 strands ranging in size from 0.122 mm to 0.178 mm, braided with an inner diameter ranging from 5 to 6 mm. In a preferred embodiment, the implant **100** has a manufactured, first diameter (inner) of about 4.0 mm to about 10.0 mm.

Various factors contribute to the radial strength of implant **100**. For woven implant structures, these factors include the diameter(s) of the strands, the braid angle **140**, the strand material(s), the number of strands used, and the use of strengthening means. The inventors have found that it is preferred that the woven implants of the present invention have a braid angle **140** within a range of about 90° to 135°, more preferably within a range of about 110° to 135°, and most preferably within a range of about 115° to 130°. The inventors have confirmed through experimentation that braid angle may affect certain mechanical properties of the implants of the present invention. For example, the inventors have found that while a braid angle of 110° for 6 mm PGCL coated braided implants made from PLGA 10:90 copolymer strands yields post-crimp RRF and COF values at 4.5 mm of 370 mm and 147 mm Hg, respectively, the same coated implants having a 127° braid angle are characterized by post-crimp RRF and COF values at 4.5 mm of 900 mm and 170 mm Hg, respectively. RRF and COF values for 7 mm PGCL coated PLGA 10:90 copolymer implants having a 140° braid angle were not obtainable because the samples buckled in the test equipment, thus demonstrating that a high braid angle may result in the inability of the implant to uniformly collapse during crimping into a catheter. Braid angle was also found to have an effect upon the ability of the implants of the present invention to recover to their as-manufactured diameters. For example, 7 mm PGCL coated braided implants made from PLGA 10:90 copolymer and having braid angles of 133°, 127°, and 110° were found to recover to about 96%, 94%, and 91% of their as-manufactured configurations, respectively, after being held at 37° C. for one hour.

In another embodiment specific to woven structures, the ends of strands are fused in patterns on the outside and/or inside of the implant **100**, as shown in FIG. 6. Fusing the strands in this manner causes the ends **132**, **133** to flare outwards instead of curling inward, thus addressing a phenomenon in which the ends of the implant may naturally curl inward when the implant is crimped into a reduced configuration for insertion into a bodily lumen or cavity. In one embodiment, the ends are fused in patterns such that their final positions are axially staggered. Strands are fused, for

example, by using heat, chemicals, adhesives, crimp swages, coatings (elastomeric or non-elastomeric), or other suitable fusing or joining techniques.

The implants of the present invention are preferably radiopaque such that they are visible using conventional fluoroscopic techniques. In one embodiment, radiopaque additives are included within the polymer material of one or more strands of implant **100**. Examples of suitable radiopaque additives include particles comprising iodine, bromine, barium sulfate, and chelates of gadolinium or other paramagnetic metals such as iron, manganese, or tungsten. In another embodiment, the radiopaque groups, such as iodine, are introduced onto the polymer backbone. In yet another embodiment, one or more biostable or biodegradable radiopaque markers, preferably comprising platinum, iridium, tantalum, and/or palladium are produced in the form of a tube, coil, sphere, or disk, which is then slid over one or more strands of fiber to attach to the ends of implant **100** or at other predetermined locations thereon. When the marker is in the form of a tube or coil, it has a preferable wall thickness of about 0.050 to 0.075 mm and a length of about 0.3 to 1.3 mm. The tube is formed by extrusion or other methods known in the art. The coil is formed by winding a wire around a mandrel of desired diameter and setting the coil with heat or other methods known in the art.

To facilitate delivery, the implant **100** is preferably loaded into a delivery catheter just prior to being implanted into a patient. Loading the implant **100** in close temporal proximity to implantation avoids the possibility that the polymer of the implant **100** will relax during shipping, storage, and the like within the delivery catheter and therefore cannot fully expand to a working configuration. As such, one aspect of the invention includes a method of delivering an implant of the invention that comprises the step of loading the implant into a delivery catheter within a short period of time, and preferably within one hour, before implantation into a body lumen. It should be noted, however, that it is not required that the implants of the present invention are loaded into delivery catheters just prior to being implanted. In fact, one advantage of the present invention is that it provides self-expanding implantable medical devices with preferred expansion characteristics and mechanical properties even after being loaded in a delivery catheter for prolonged periods.

The present invention is further described with reference to the following non-limiting examples.

#### Example 1

Braided implants were manufactured using a PLGA 10:90 copolymer by spooling fiber spun monofilaments onto individual bobbins. Each bobbin was placed on a braiding machine, strung through rollers and eyelets and wrapped around a mandrel. The braiding tension of the machine was set for the size of the monofilament (i.e., 70 g min, 215 g max for 0.005" fiber). The pix/inch was set to obtain an ideal angle to maximize radial strength but still allow the braid to be removed from the mandrel (i.e., 110 to 135 degrees for a 6 mm mandrel). The braid pattern was selected and the monofilaments were braided off the spool onto the mandrel by the braiding machine. Tiewraps were used on the end of each mandrel to keep the tension on the filaments, which can be important for heat annealing and obtaining high modulus properties. The braided polymer was heat annealed on the mandrel, and then cut into desired lengths with a blade and removed from the mandrel. A representative implant was measured to have an outer diameter of about 6.0 mm and a length of about 20 mm.



## 11

Implants were coated with a support coating made from poly(glycolide-co-caprolactone) (PGCL) cured with hexamethylene diisocyanate. The PGCL 50:50 copolymer was prepared as follows. A 100 mL round-bottom flask was dried in oven at 110° C. and then cooled to room temperature under a nitrogen atmosphere. The flask was charged with Sn(Oct)<sub>2</sub> (15 mg), pentaerythritol (68 mg), glycolide (10.0 g), and ε-caprolactone (10.0 g), respectively. Subsequently, the flask was equipped with a magnetic stir bar and a three-way valve connected to a nitrogen balloon. The flask was thoroughly degassed under reduced pressure and flushed with nitrogen. The flask was then placed into an oil bath which was preheated to 170° C. The reaction was stirred at 170° C. for 24 h under a nitrogen atmosphere. After cooling to room temperature, the solid obtained was dissolved in dichloromethane and precipitated from anhydrous diethyl ether. The solution was decanted and the residual sticky solid was washed thoroughly with diethyl ether and dried in vacuum. Typically, around 18 g of polymer was recovered through the purification. GPC characterization revealed a number average molecular weight (Mn) of 39,900 and a polydispersity index (PDI) of 1.23.

The four-arm PGCL 50:50 (1.0 g) and HDI (375 μL) were dissolved in 20 mL dichloromethane to make a stock solution for spray-coating. A steel mandrel of 2 mm in diameter was mounted vertically onto a mechanical stirrer, and the braided implant was placed over the mandrel. A spray gun (Badger 150) was arranged perpendicular to the mandrel, and connected to a nitrogen cylinder and a reservoir containing the stock solution. The mechanical stirrer was turned on to spin the mandrel and the solution was sprayed onto the braid by applying the nitrogen flow. The coating weight could be controlled by the spray time. After spray coating, devices were dried in air for 1 h and then cured at 100° C. for 16 h. A catalyst such as tin octanoate or zinc octanoate may also be used in the curing process to reduce the curing time and/or temperature.

Coated devices were placed in an MSI radial force tester to obtain RRF and COF values, both measured in mm Hg, at time points prior to and subsequent to crimping the device to 2.5 mm.

The inventors surprisingly found that whereas uncoated implants were able to recover to only about 50% of their original diameter after being crimped at 37° C. for one hour, the application of the PGCL/HDI coating resulted in a recovery of up to about 95% of the device original diameter. This effect was found to be at least partially dependent upon the coating weight on the implant. As illustrated in FIG. 7, diameter recovery was found to be related to the mass increase attributable to the application of the coating (i.e., coating weight), with an appreciable increase in the diameter recovery ability beginning when the increase in implant mass due to the application of the coating is about 15%. The effect of coating weight levels off when the increase in implant mass due to the application of the coating is at least about 20%, at which point the device recovery diameter is at least about 90%.

Implant diameter recovery was also affected by the percent gel content in the coating, as shown in FIG. 8. Gel content is defined as the quantity of coating that is sufficiently crosslinked so that it is no longer soluble in a solvent. The calculation of gel content in the PGCL/HDI coating is described in Example 3. The inventors have found in this Example that a coating gel content of greater than about 80% is preferred to achieve a diameter recovery of at least about 90%.

Table I shows the percent recovery, radial resistive force (RRF) at a post-crimp diameter of 4.5 mm, and chronic out-

## 12

ward force (COF) at a post-crimp diameter of 4.5 mm, for coated implants with varying coating weight. As can be seen from the data in Table I, the support coating increased the post-crimp recovery ability, RRF, and COF of the implants. Moreover, in addition to increasing recoverability of the implant acutely (i.e., after being crimped one hour in a 37° C. water bath), the support coating is able to increase recoverability chronically (i.e., after being crimped for five days at room temperature in air).

TABLE I

Percent recovery, RRF, and COF for coated implant samples that were crimped to 2.5 mm and held in water bath at 37° C. The percent increase in implant weight due to the coating is shown in the Sample Description column.						
Sample No.	Sample Description	Water Bath Treatment	% Recovery after 2.5 mm Crimp	RRF at 4.5 mm (mmHg)	COF at 4.5 mm (mmHg)	
1	10:90 PLGA uncoated	1 hour	48	83.4	11.6	
2	10:90 PLGA coated 45%	1 hour	93.5	—	—	
3	10:90 PLGA coated 41%	1 hour	94.5	645.0	245.0	
4	10:90 PLGA coated 33%	1 hour	94.6	—	—	
5	10:90 PLGA coated 33%	5 days at room T in air (no water bath)	94.4	—	—	
6	10:90 PLGA coated 24%	1 hour	91.5	1030.0	188.0	
7	10:90 PLGA coated 22%	1 hour	77.9	897.0	84.0	
8	10:90 PLGA coated 17%	1 hour	65.6	559.0	24.4	
9	10:90 PLGA coated 15%	1 hour	58.2	—	—	
10	10:90 PLGA coated 13%	1 hour	51.4	393.0	-2.6	
11	PDO uncoated	1 hour	79.0	53.4	0	
12	PDO coated 37%	1 hour	83.6	863.0	115.0	

## Example 2

Implants and coating solutions were manufactured as described in Example 1. Instead of being applied uniformly to the implants, support coatings were applied to just the ends of the implants (i.e., approximately 4-5 mm at each end). Whereas the uncoated implant was able to recover only about 48% of its original diameter after being crimped to 2.5 mm and held in a water bath for one hour at 37° C., the implant coated at its ends was able to recover, under the same conditions, to about 82% of its original diameter. Moreover, for these same implants, the RRF and COF was increased from 83.4 mmHg and 11.6 mmHg to 595.0 mmHg and 55.0 mmHg, respectively.

## Example 3

The gel content of a coated implant (such as the implant described in Example 1) was measured via extraction. The PGCL/HDI coated device was placed in 5 mL of dichloromethane and shaken at room temperature for about 1 hour. The solvent was removed, and the device was rinsed thor-

## 13

oughly with dichloromethane and subsequently allowed to air dry for about 10 minutes. The device was placed in a convection oven at 100° C. to remove any residual solvent. The gel content in the coating was then determined using the following equation: % gel content in coating=((mass of coated device after extraction-mass of uncoated device)/(mass of coated device before extraction-mass of uncoated device))×100. A control experiment on the uncoated woven PLGA 10:90 structure showed no appreciable mass loss in a similar experiment.

## Example 4

A pattern was laser cut into a tubular base material to produce self-expanding medical implants. Some of the implants were coated with a support coating made from PGCL cured with HDI, as described in Example 1. Similar to the previous examples, coated implants demonstrated higher RRF and COF properties as compared with uncoated implants.

## Example 5

Braided implants having an as-manufactured diameter of 6 mm were manufactured using a PLGA 75:25 copolymer using a manufacturing process similar to that of Example 1. The implants were coated with a support coating made from PLCL 50:50 prepared as follows. A 250 mL round-bottom flask was dried in an oven at 110° C. and cooled to room temperature in a nitrogen atmosphere. The flask was charged with Sn(Oct)<sub>2</sub> (11.5 mg), pentaerythritol (204 mg), lactide (30.0 g), and ε-caprolactone (30.0 g), respectively. Subsequently, the flask was equipped with a magnetic stir bar and a three-way valve connected to a nitrogen balloon. The flask was thoroughly degassed under reduced pressure and flushed with nitrogen. The flask was then placed into an oil bath which was preheated to 170° C. The reaction was stirred at 170° C. for 48 h under a nitrogen atmosphere. After cooling to room temperature, the highly viscous liquid obtained was dissolved in approximately 200 mL dichloromethane and precipitated from 1200 mL anhydrous diethyl ether. The solution was decanted and the residual sticky polymer was washed thoroughly with diethyl ether and dried under vacuum. Typically, around 48 g polymer was recovered through the purification. GPC characterization revealed a number average molecular weight (Mn) of 52,500 and a polydispersity index (PDI) of 1.2.

Coated devices were crimped to 1.85 mm in a MSI radial force tester (Model#RX550-100) to obtain RRF and COF values, both measured in mm Hg, at a diameter of 4.5 mm for 6 mm device and at a diameter of 5.5 mm for 7 mm device. Like the implants coated with PGCL described in Example 1, both RRF and COF were found to be directly proportional to the coating weight. The inventors note that both RRF and COF for the coated devices are significantly higher than for uncoated devices. For example, a 7 mm implant having an increase in weight due to the PLCL/HDI coating of about 45% resulted in RRF of about 450 mm Hg and COF of 90 mm Hg, measured at 4.5 mm, while the uncoated device resulted in RRF and COF of 80 mm and 0 mm Hg, respectively.

## Example 6

Braided implants having an as-manufactured diameter of 6 mm were manufactured using a PLGA 75:25 copolymer using a manufacturing process similar to that of Example 1. The implants were coated with a support coating made from

## 14

poly trimethylene carbonate (PTMC) and hexamethylenediisocyanate. The PTMC three arm polymer was prepared as follows. A 100 mL round-bottom flask, previously dried under heat and vacuum, was charged with Sn(Oct)<sub>2</sub> (20 mg), triethanolamine (298.4 mg) and trimethylene carbonate (30 g) respectively. Subsequently, the flask was equipped with a magnetic stir bar and a three-way valve connected to a nitrogen balloon. The flask was thoroughly degassed under reduced pressure and flushed with nitrogen and then placed into an oil bath which was preheated to 70° C. The oil bath temperature was then increased to 100° C. over 15 minutes. The reaction was stirred at 100° C. for 23 h under a nitrogen atmosphere. After cooling to room temperature, the viscous liquid obtained was dissolved overnight in approximately 50 mL dichloromethane and subsequently precipitated from 550 mL ethanol. The precipitated polymer was stirred for one hour after which the ethanol was decanted. The process of dissolving the polymer in dichloromethane and precipitating in ethanol was repeated. The polymer was then dissolved in dichloromethane, precipitated into 550 mL diethyl ether and stirred for one hour after which time the diethyl ether was decanted. The polymer was then dried under vacuum @ 70° C. for a period of 72 hours. Typically 24 g of polymer was recovered using above process. GPC characterization of the final polymer revealed a number average molecular weight (Mn) of 29 kDa and a polydispersity index (PDI) of 2.0.

An MSI radial force tester (Model#RX550-100) was used to obtain radial resistive force ("RRF") and chronic outward force ("COF"), at a post-crimp diameter of 4.5 mm for PTMC/HDI coated devices. For example, a 6 mm implant having an increase in weight due to the PTMC/HDI support coating of about 50% resulted in RRF of 490 mm Hg and COF of 83 mm Hg, measured at 4.5 mm. PTMC is considered to be a surface-degrading material which does not generate acidic by-products upon degradation.

## Comparative Example 1

Implants of the present invention were compared to several commercially available, biostable self-expanding implants, namely the VIABAHN® Endoprosthesis (a self-expanding nitinol stent-graft from W.L. Gore & Associates, Inc.), the S.M.A.R.T.® stent (a self-expanding nitinol stent from Cordis Corp.), and the WALLSTENT® Endoprosthesis (a self-expanding steel stent from Boston Scientific Corp.). Specifically, the RRF and COF values of these commercially available implants were measured and compared with 6 mm (having a 127° braid angle) and 7 mm (having braid angles of 127° and 110°) diameter implants made from PLGA 75:25. The PLGA implants were made using a manufacturing process similar to that of Example 1, and coated with a support coating made from PLCL 50:50 copolymer and hexamethylenediisocyanate as described in Example 5 with a coating weight of between 44% and 50% for the 7 mm devices and a weight of 47% to 57% for the 6 mm devices. RRF and COF values were measured at post-crimp diameters corresponding to the range of intended target vessel diameters. The results demonstrated that the implants of the present invention are characterized by mechanical properties such as RRF and COF that are comparable to their commercially available metallic counterparts.

## Comparative Example 2

Braided implants having an as-manufactured diameter of 6 mm were manufactured using a PLGA 75:25 copolymer using a manufacturing process similar to that of Example 1.

15

One set of implants were coated with a support coating comprising PGCL 50:50 and hexamethylenediisocyanate, and another set of implants were coated with a support coating comprising PLCL 50:50 and hexamethylenediisocyanate. The implants were deployed into vessel-compliant tubing and maintained at 37° C. under simulated flow conditions for 0, 7, 14, and 28 days. At those time points, the implants were explanted from the tubing, dried overnight, and the COF of the implants was measured at a post-crimp diameter of 4.5 mm. The results are shown in FIG. 9, which demonstrate that the COF for both sets of implants decrease over time, with COF going to zero for the PGCL coated implants as of 28 days. Also shown in FIG. 9 are the COF values measured for the S.M.A.R.T. stent and WALLSTENT Endoprosthesis as described in Comparative Example 1, which are constant because those devices are metallic and do not degrade or relax over time. The inventors believe that the significant decrease in COF over time for the implants of the present invention is an advantage over their metallic stent counterparts because a continuous force applied by implants against surrounding tissue over time may result in chronic irritation and inflammation leading to restenosis.

The present invention provides woven and non-woven self-expanding medical implants for placement within a bodily lumen that have sufficient strength and other mechanical properties that are necessary to effectively treat a variety of medical conditions. While aspects of the invention have been described with reference to example embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention.

We claim:

1. An implantable medical device, comprising: a self-expanding tubular structure comprising
  - at least one strand comprising a first biodegradable material; and
  - a second biodegradable material at least partially conformally coating said strand; wherein said tubular structure comprises a first diameter greater than 2.5 mm, and said tubular structure recovers to at least 90% of said first diameter after being crimped to a diameter that is less than 50% of said first diameter,
 wherein said first diameter is a manufactured diameter of said tubular structure.
2. The implantable medical device of claim 1, wherein said first biodegradable material comprises poly(lactic acid co-glycolic acid).
3. The implantable medical device of claim 2, wherein said poly(lactic acid co-glycolic acid) comprises at least about 75 weight percent of lactic acid.
4. The implantable medical device of claim 2, wherein said poly(lactic acid co-glycolic acid) comprises about 85 weight percent of lactic acid.
5. The implantable medical device of claim 2, wherein said poly(lactic acid co-glycolic acid) comprises up to about 20 weight percent of lactic acid.
6. The implantable medical device of claim 1, wherein said second biodegradable material is a random copolymer that is crosslinked.
7. The implantable medical device of claim 1, wherein said second biodegradable material is selected from the group consisting of poly(lactic acid-co-caprolactone), poly(glycolide-co-caprolactone), poly(trimethylene carbonate), and poly(lactic acid-co-dioxanone).

16

8. The implantable medical device of claim 7, wherein said second biodegradable material is poly(lactic acid-co-caprolactone) comprising about 50 to 70 weight percent lactic acid.

9. The implantable medical device of claim 8, wherein said poly(lactic acid-co-caprolactone) is crosslinked with hexamethylene diisocyanate.

10. The implantable medical device of claim 1, further comprising a therapeutic agent within at least one of said first biodegradable material and said second biodegradable material.

11. An implantable medical device, comprising:

- a self-expanding tubular structure comprising
  - at least one strand comprising a first biodegradable polymer; and
  - a second biodegradable polymer conformally coating said strand, said second polymer being a thermoset copolymer;

wherein said tubular structure:

- comprises a first diameter greater than 4.5 mm;
  - recovers to at least 90% of said first diameter after being crimped to a diameter that is less than 50% of said first diameter; and
  - exerts a force against a blood vessel wall immediately after being implanted in said blood vessel, wherein said force decreases over time,
- and wherein said first diameter is a manufactured diameter of said tubular structure.

12. The implantable medical device of claim 11, wherein said first diameter is at least about 6.0 mm.

13. The implantable medical device of claim 11, wherein said first diameter is at least about 7.0 mm.

14. An implantable medical device, comprising: a self-expanding tubular structure comprising

- at least one strand comprising a first biodegradable material; and
  - a second biodegradable material at least partially conformally coating said strand; wherein said tubular structure comprises a first diameter greater than 2.5 mm, and said tubular structure recovers to at least 90% of said first diameter after being crimped to a diameter that is less than 70% of said first diameter,
- wherein said first diameter is a manufactured diameter of said tubular structure.

15. The implantable medical device of claim 14, wherein said first diameter is at least about 6.0 mm.

16. An implantable medical device, comprising:

- a self-expanding tubular structure comprising
  - at least one strand comprising a first biodegradable polymer; and
  - a second biodegradable polymer conformally coating said strand, said second polymer being a thermoset copolymer;

wherein said tubular structure:

- comprises a first diameter greater than 4.5 mm;
  - recovers to at least 90% of said first diameter after being crimped to a diameter that is less than 70% of said first diameter; and
  - exerts a force against a blood vessel wall immediately after being implanted in said blood vessel, wherein said force decreases over time,
- and wherein said first diameter is a manufactured diameter of said tubular structure.

\* \* \* \* \*